SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-046752
Filing Date
2024-04-12
Accepted
2024-04-12 16:04:55
Documents
16
Period of Report
2024-04-12
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2411708d1_8k.htm   iXBRL 8-K 28695
2 EXHIBIT 5.1 tm2411708d1_ex5-1.htm EX-5.1 11716
3 EXHIBIT 10.1 tm2411708d1_ex10-1.htm EX-10.1 16863
7 GRAPHIC tm2411708d1_ex5-1img01.jpg GRAPHIC 2639
  Complete submission text file 0001104659-24-046752.txt   246286

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA otlk-20240412.xsd EX-101.SCH 3048
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20240412_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20240412_pre.xml EX-101.PRE 22381
19 EXTRACTED XBRL INSTANCE DOCUMENT tm2411708d1_8k_htm.xml XML 3777
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 24841423
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)